EODData

MEMBERSHIP REGISTER LOG IN

FRA, J7Z: Jazz Pharmaceuticals plc

19 Dec 2025
LAST:

142.4

CHANGE:
 1.00		OPEN:
140.5		HIGH:
143.2		ASK:
0.0		VOLUME:
50
CHG(%):
0.71		PREV:
141.4		LOW:
140.5		BID:
0.0		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
19 Dec 25140.5143.2140.5142.450
18 Dec 25139.2141.4138.3141.450
17 Dec 25143.1144.0140.5140.5120
16 Dec 25141.4146.0141.4144.2120
15 Dec 25141.4144.4141.2144.040
12 Dec 25138.6142.8138.6142.340
11 Dec 25137.7142.0137.7140.3178
10 Dec 25137.8140.9137.8140.9178
09 Dec 25143.4145.1139.1139.140
08 Dec 25144.1146.4144.1144.940

PROFILE

Name:Jazz Pharmaceuticals plc
About:Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Xyrem for the treatment of cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Defitelio to treat severe veno-occlusive disease; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab in Phase 3 trial to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Epidiolex in Phase 3 trial to treat LGS, DS, and TSC; Suvecaltamide in Phase 2 trial to treat Parkinson's disease tremor; JZP815, a pan-RAF kinase inhibitor in Phase 1 trial that targets components of the mitogen-activated protein kinase; JZP898, a conditionally activated interferon alpha molecule in Phase 1 trial; JZP441 in Phase 1 trial to treat narcolepsy, IH, and other sleep disorders; JZP324, an extended-release low sodium oxybate formulation in Phase 1 trial for patients with sleep disorders; and JZP150 to treat post-traumatic stress disorder. The company has licensing and collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., and Werewolf Therapeutics, Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.
Sector:Healthcare
Industry:Biotechnology
Address:Waterloo Exchange, Dublin, Ireland, D04 E5W7
Website:https://www.jazzpharma.com
ISIN:IE00B4Q5ZN47

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:15.69 
Forward P/E:6.78 
PEG Ratio:-0.03 
Price to Sales:1.78 
Price to Book:1.96 
Profit Margin:-0.10 
Operating Margin:0.21 
Return on Assets:0.05 
Return on Equity:-0.11 
Revenue:3.547B 
EBITDA:1.117B 
Shares:60.66M 
Market Cap:8.635B 

TECHNICAL INDICATORS

MA5:142.460.1%
MA10:141.960.3%
MA20:145.502.2%
MA50:132.247.6%
MA100:119.4719.2%
MA200:110.1529.2%
STO9:47.48
STO14:38.15
RSI14:39.92 
WPR14:-49.62
MTM14:-1.00
ROC14:-0.01 
ATR:3.68 
Week High:146.002.6%
Week Low:138.253.0%
Month High:158.2511.2%
Month Low:137.7029.2%
Year High:158.2511.2%
Year Low:85.5566.4%
Volatility:7.88